2023
DOI: 10.1021/acs.accounts.3c00440
|View full text |Cite
|
Sign up to set email alerts
|

N6-Methyladenosine mRNA Modification: From Modification Site Selectivity to Neurological Functions

Zeyu Zhang,
Xiu-Jie Wang
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 43 publications
0
2
0
Order By: Relevance
“…The modification of m6A is completed by methyltransferase complexes such as methyltransferase-like (METTL)-3, METTL-14, Wilms Tumor 1-associated protein, RNA-binding motif protein 15 and zinc finger CCCH domain-containing protein 13 ( 4 , 120-124 ). Various internal or external factors, such as cell type, developmental stage, nutrient supply, circadian rhythm and environmental stresses initiate m6a translation ( 125 ). The 5'UTR m6A residue can directly recruit eukaryotic initiation factor 3, which is sufficient to recruit the 43S pre-initiation complex and bypass the m7G capping requirement to initiate translation, thus enabling translation initiation in the absence of the cap-binding factor eIF4E model ( 126 ).…”
Section: Mechanisms and Clinical Application Of Circrnasmentioning
confidence: 99%
“…The modification of m6A is completed by methyltransferase complexes such as methyltransferase-like (METTL)-3, METTL-14, Wilms Tumor 1-associated protein, RNA-binding motif protein 15 and zinc finger CCCH domain-containing protein 13 ( 4 , 120-124 ). Various internal or external factors, such as cell type, developmental stage, nutrient supply, circadian rhythm and environmental stresses initiate m6a translation ( 125 ). The 5'UTR m6A residue can directly recruit eukaryotic initiation factor 3, which is sufficient to recruit the 43S pre-initiation complex and bypass the m7G capping requirement to initiate translation, thus enabling translation initiation in the absence of the cap-binding factor eIF4E model ( 126 ).…”
Section: Mechanisms and Clinical Application Of Circrnasmentioning
confidence: 99%
“…N 6 -methyladenosine (m 6 A) stands as one of the most abundant and prevalent modifications across mammalian RNA species . m 6 A is present in a variety of RNA types, encompassing mRNA, rRNA, tRNA, miRNA, and long noncoding RNAs. , m 6 A can significantly influence RNA structure, stability, and translation efficiency. Moreover, m 6 A is acknowledged for its vital participation in regulatory networks, including gene expression regulation, developmental pathways, carcinogenesis, and the immune response to viral infections, highlighting its fundamental role in cellular and molecular biology. …”
Section: Introductionmentioning
confidence: 99%